Causes or consequences of inflammation and pathological signs of Alzheimer disease

Neurobiology of Aging

Volumn 21, Issue 3, 2000, Pages 423-425

  Roses, Allen D ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; BRAIN METABOLISM; COGNITIVE DEFECT; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; INFLAMMATION; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034612090     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00142-1     Document Type: Note

References (24)

1. Corder E.H., Saunders A.M., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet. 7:1994;180-184.
2. Corder EH, Saunders AM, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 1993;261:921-3.
3. Goedert M., Spillantini M.G., et al. Tau gene mutation in familial progressive subcortical gliosis. Nature Med. 5:1999;454-457.
4. Holtzman D.M., Bales K.R., et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest. 103:1999;R15-R21.
5. LaDu M.J., Falduto M.T., et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 269:1994;23403-23406.
6. Lanzrein A.S., Johnston C.M., et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease interleukin-1 beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin . Alzheimer Dis Assoc Disord. 12:1998;215-227.
7. Mirra S.S., Murrell J.R., et al. Tau pathology in a family with dementia and a P301L mutation in tau. J Neuropathol Exp Neurol. 58:1999;335-345.
8. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. New England Journal of Medicine 1995 Nov 9;333(19):1242-7.
9. Rebeck G.W., Reiter J.S., et al. Apolipoprotein E in sporadic Alzheimer's disease allelic variation and receptor interactions . Neuron. 11:1993;575-580.
10. Reed T., Carmelli D., et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol. 51:1994;1189-1192.
11. Reiman E.M., Caselli R.J., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 334:1996;752-758.
12. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining Brain Activity in Cognitively Normal Apolipoprotein E ε4 Heterozygotes: A Foundation for Testing Alzheimer's Disease Prevention Therapies Using Positron Emission Tomography, 2000 submitted for publication.
13. Roses A.D. Apolipoprotein E affects the rate of Alzheimer disease expression beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease . J Neuropathol Exp Neurol. 53:1994;429-437.
14. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer disease. Ann Rev Med. 47:1996;387-400.
15. Roses A.D. Genetic testing for Alzheimer disease. Practical and ethical issues. Arch Neurol. 54:1997;1226-1229.
16. Schmechel D.E., Saunders A.M., et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 90:1993;9649-9653.
17. Selkoe D.J. Alzheimer's disease a central role for amyloid. (Review) . J Neuropathol Exp Neurol. 53:1994;438-447.
18. Sherrington R., Froelich S., et al. Alzheimer's disease associated with mutations in presenilin-2 are rare and variably penetrant. Human Mol Genet. 5:1996;985-988.
19. Small GW, Ercoli LM, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences USA 2000:97(11).
20. Small G.W., Mazziotta J.C., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. J Am Med Assoc. 273:1995;942-947.
21. Sorbi S., Nacmias B., et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol. 38:1995;124-127.
22. Spillantini MG, Murrell JR, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proceedings of the National Academy of Sciences of the United States of America 1998;95:7737-41.
23. St. George-Hyslop P, McLachlan DC, et al. Alzheimer's disease and possible gene interaction (letter) (published erratum appears in Science 1994; Feb 18;263(5149):904). Science 1994;263:537.
24. St. George-Hyslop P, McLachlan DC, et al. Alzheimer's disease and possible gene interaction (letter) (published erratum appears in Science 1994; Feb 18;263(5149):904). Science 1994;263:537.